# CLINICAL RESEARCH PROTOCOL [A Phase I, Single-arm, Open-label, Dose-escalation Clinical Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers]

> **NCT07300202** · PHASE1 · COMPLETED · sponsor: **Oriplantee Company Limited** · enrollment: 15 (actual)

## Conditions studied

- Evaluate the Safety Profile and Tolerability of Orialpha in Healthy Adult Volunteers
- Breast Cancer

## Interventions

- **DRUG:** Orialpha (BD-C)

## Key facts

- **NCT ID:** NCT07300202
- **Lead sponsor:** Oriplantee Company Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-13
- **Primary completion:** 2025-06-16
- **Final completion:** 2025-08-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-12-23

## Collaborators

- Vietstar Biomedical Research

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07300202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07300202, "CLINICAL RESEARCH PROTOCOL [A Phase I, Single-arm, Open-label, Dose-escalation Clinical Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers]". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT07300202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*